495 related articles for article (PubMed ID: 26961869)
21. An activin-A/C chimera exhibits activin and myostatin antagonistic properties.
Muenster U; Harrison CA; Donaldson C; Vale W; Fischer WH
J Biol Chem; 2005 Nov; 280(44):36626-32. PubMed ID: 16129674
[TBL] [Abstract][Full Text] [Related]
22. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
[TBL] [Abstract][Full Text] [Related]
23. mRNA expression of type I and type II receptors for activin, transforming growth factor-beta, and bone morphogenetic protein in the murine erythroleukemic cell line, F5-5.fl.
Machida H; Ogawa K; Funaba M; Mizutani T; Tsujimoto M
Eur J Endocrinol; 2000 Nov; 143(5):705-10. PubMed ID: 11078996
[TBL] [Abstract][Full Text] [Related]
24. Development of novel activin-targeted therapeutics.
Chen JL; Walton KL; Al-Musawi SL; Kelly EK; Qian H; La M; Lu L; Lovrecz G; Ziemann M; Lazarus R; El-Osta A; Gregorevic P; Harrison CA
Mol Ther; 2015 Mar; 23(3):434-44. PubMed ID: 25399825
[TBL] [Abstract][Full Text] [Related]
25. A new model for growth factor activation: type II receptors compete with the prodomain for BMP-7.
Sengle G; Ono RN; Lyons KM; Bächinger HP; Sakai LY
J Mol Biol; 2008 Sep; 381(4):1025-39. PubMed ID: 18621057
[TBL] [Abstract][Full Text] [Related]
26. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
[TBL] [Abstract][Full Text] [Related]
27. Biochemical and Cellular Analysis Reveals Ligand Binding Specificities, a Molecular Basis for Ligand Recognition, and Membrane Association-dependent Activities of Cripto-1 and Cryptic.
Aykul S; Parenti A; Chu KY; Reske J; Floer M; Ralston A; Martinez-Hackert E
J Biol Chem; 2017 Mar; 292(10):4138-4151. PubMed ID: 28126904
[TBL] [Abstract][Full Text] [Related]
28. Type II BMP and activin receptors BMPR2 and ACVR2A share a conserved mode of growth factor recognition.
Chu KY; Malik A; Thamilselvan V; Martinez-Hackert E
J Biol Chem; 2022 Jul; 298(7):102076. PubMed ID: 35643319
[TBL] [Abstract][Full Text] [Related]
29. Inhibin is an antagonist of bone morphogenetic protein signaling.
Wiater E; Vale W
J Biol Chem; 2003 Mar; 278(10):7934-41. PubMed ID: 12493742
[TBL] [Abstract][Full Text] [Related]
30. BMPR2 inhibits activin and BMP signaling via wild-type ALK2.
Olsen OE; Sankar M; Elsaadi S; Hella H; Buene G; Darvekar SR; Misund K; Katagiri T; Knaus P; Holien T
J Cell Sci; 2018 Jun; 131(11):. PubMed ID: 29739878
[TBL] [Abstract][Full Text] [Related]
31. TGF-β family co-receptor function and signaling.
Nickel J; Ten Dijke P; Mueller TD
Acta Biochim Biophys Sin (Shanghai); 2018 Jan; 50(1):12-36. PubMed ID: 29293886
[TBL] [Abstract][Full Text] [Related]
32. Structural and functional evidence for a singular repertoire of BMP receptor signal transducing proteins in the lophotrochozoan Crassostrea gigas suggests a shared ancestral BMP/activin pathway.
Herpin A; Lelong C; Becker T; Rosa F; Favrel P; Cunningham C
FEBS J; 2005 Jul; 272(13):3424-40. PubMed ID: 15978047
[TBL] [Abstract][Full Text] [Related]
33. Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome.
Kotzsch A; Nickel J; Seher A; Heinecke K; van Geersdaele L; Herrmann T; Sebald W; Mueller TD
J Biol Chem; 2008 Feb; 283(9):5876-87. PubMed ID: 18160401
[TBL] [Abstract][Full Text] [Related]
34. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
Tsuchida K; Nakatani M; Uezumi A; Murakami T; Cui X
Endocr J; 2008 Mar; 55(1):11-21. PubMed ID: 17878607
[TBL] [Abstract][Full Text] [Related]
35. New Ligand Binding Function of Human Cerberus and Role of Proteolytic Processing in Regulating Ligand-Receptor Interactions and Antagonist Activity.
Aykul S; Martinez-Hackert E
J Mol Biol; 2016 Feb; 428(3):590-602. PubMed ID: 26802359
[TBL] [Abstract][Full Text] [Related]
36. Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.
Olsen OE; Hella H; Elsaadi S; Jacobi C; Martinez-Hackert E; Holien T
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32235336
[TBL] [Abstract][Full Text] [Related]
37. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
Upton PD; Davies RJ; Trembath RC; Morrell NW
J Biol Chem; 2009 Jun; 284(23):15794-804. PubMed ID: 19366699
[TBL] [Abstract][Full Text] [Related]
38. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions.
Thompson TB; Woodruff TK; Jardetzky TS
EMBO J; 2003 Apr; 22(7):1555-66. PubMed ID: 12660162
[TBL] [Abstract][Full Text] [Related]
39. Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors.
Breen MJ; Moran DM; Liu W; Huang X; Vary CP; Bergan RC
PLoS One; 2013; 8(8):e72407. PubMed ID: 23967299
[TBL] [Abstract][Full Text] [Related]
40. BAMBI (bone morphogenetic protein and activin membrane-bound inhibitor) reveals the involvement of the transforming growth factor-beta family in pain modulation.
Tramullas M; Lantero A; Díaz A; Morchón N; Merino D; Villar A; Buscher D; Merino R; Hurlé JM; Izpisúa-Belmonte JC; Hurlé MA
J Neurosci; 2010 Jan; 30(4):1502-11. PubMed ID: 20107078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
